Pre-Open Movers 7/3: NVIDIA (NVDA) Clobbered On Warning, Chindex (CHDX) Up on China Approvals

July 3, 2008 9:23 AM EDT

StreetInsider.com Pre-Open Movers:

NVIDIA Corporation (Nasdaq: NVDA) 26% LOWER; sees Q2 revenue of $875 million to $950 million, below the consensus of $1.1 billion. The estimated decrease in revenue and gross margin is due to several reasons: end-market weakness around the world, the delayed ramp of a next generation MCP, and price adjustments of our GPU products to respond to competitive products.

Acme Packet, Inc. (NASDAQ: APKT) 20% LOWER; sees Q2 revenues between $24.5 million and $25.5 million and Non-GAAP EPS of $0.02. The Wall Street consensus is $33.6 million and $0.09.

TranS1 Inc. (Nasdaq: TSON) 18% LOWER; announced that revenues for the second quarter of 2008 are expected to be approximately $5.9 to $6.0 million, lower than previously announced guidance of $6.3 to $6.5 million.

Chindex International Inc. (NASDAQ: CHDX) 17% HIGHER; received long-awaited approval from the State Food and Drug Administration of the People's Republic of China to introduce new products, including the daVinci S Surgical System manufactured by Intuitive Surgical and the AlexLaser manufactured by Candela Corporation.

ARYx Therapeutics, Inc., (NASDAQ: ARYX) 13% LOWER; announced the results of an important cardiac safety study on its prokinetic agent, ATI-7505. The overall results of a Thorough QT (TQT) study designed to demonstrate whether electrocardiographic effects are seen at therapeutic and supra therapeutic doses and conducted under a collaboration agreement with Procter & Gamble Pharmaceuticals (P&G) were negative, supporting the favorable cardiac safety profile of the agent. ATI-7505 is a prokinetic agent in Phase 2 clinical trials for chronic constipation and functional dyspepsia. Seperatly, ARYx Therapeutics announced that Procter & Gamble Pharmaceuticals, Inc. (P&G) has utilized a one-time thirty day cancellation option linked to the completion of a Thorough QT (TQT) study to end the collaboration agreement between the companies covering the late-stage development and commercialization of ATI-7505, a prokinetic agent in Phase 2 clinical trials for chronic constipation and functional dyspepsia.

Penn National Gaming Inc. (Nasdaq: PENN) 10% LOWER; According to reports from CNBC's David Faber, Penn National Gaming Inc. has reached an agreement with private equity firms Fortress and Centerbridge to terminate the pending merger agreement. As part of the deal, Penn National will receive $1.475 billion, which includes a cash termination fee and an equity infusion.

Health Net Inc. (NYSE: HNT) 8% LOWER; Goldman cuts to Sell

Zoran Corp. (Nasdaq: ZRAN) 3.8% LOWER; Rumored suitor, NVIDIA, warned after the close.

Aetna Inc. (NYSE: AET) 3% LOWER; Goldman cuts to Sell

Advanced Micro Devices (NYSE: AMD) 2.8% LOWER; NVIDIA warning.

Alpha Natural Resources Inc. (NYSE: ANR) 2.8% LOWER; Continues today's 16% sell-off related to global profit-taking in commodities

Yahoo! Inc. (Nasdaq: YHOO) 2.8% HIGHER; Reports from WSJ the company pursues talks with new partners.

Abbott (NYSE: ABT) 1.5% HIGHER; announced that the FDA approved the XIENCE V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE V is the only drug eluting stent to have demonstrated superiority over Boston Scientific's TAXUS paclitaxel-eluting coronary stent system in two randomized head-to-head clinical trials. XIENCE V will be launched in the United States immediately.

Get This Report E-Mailed To You Daily and Much, Much More With StreetInsider.com Premium - FREE TRIAL

Related Categories

Special Reports

Stocks Mentioned

Related Entities

• David Faber

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?